CN Bio Innovations is an advanced bioengineering company developing microphysiological systems, colloquially referred to as Organs-on-Chips, designed to recapitulate human organ function, using proprietary microfluidic instrumentation that functions in common laboratory settings. CN Bio has extensive experience with its PhysioMimix® technology, launched in 2018. The platform has been used for a range of applications, from toxicology to complex disease models, including models of non-alcoholic steatohepatitis (NASH) and a 10-organ “Body-on-a-Chip”. As a result, CN Bio has significant experience in the culture of numerous organ tissue types both individually and in multi-organ systems. CN Bio’s objective is the development of instruments that enable high precision human biology in vitro that accurately predict the effects of chemical or biological substances in humans.

https://cn-bio.com/